Physician profile
Min Sun
NPI 1811961121
$1,438.83
in general payments reported to CMS, 2019-2025
9 companies · $255 in 2025
The $255 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $172 · 2021: $207 · 2022: $119 · 2023: $553 · 2024: $134 · 2025: $255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $920.20 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $314.58 | 2020-2023 | Opdivo |
| Beigene USA, INC. | $258.50 | 2023-2024 | Brukinsa |
| Astrazeneca Pharmaceuticals Lp | $221.54 | 2023-2025 | Enhertu |
| Eisai INC. | $169.99 | 2020-2021 | |
| Beone Medicines USA, INC. | $133.50 | 2025 | Tevimbra |
| Exelixis INC. | $125.00 | 2023 | Cabometyx |
| Rigel Pharmaceuticals, INC. | $118.52 | 2022 | |
| Exact Sciences Corporation | $76.20 | 2023 | |
| Mirati Therapeutics, INC. | $21.00 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Min Sun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.